Krishna Vaddi Acquires 10,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi bought 10,000 shares of the company’s stock in a transaction on Monday, December 30th. The stock was bought at an average price of $1.20 per share, for a total transaction of $12,000.00. Following the completion of the purchase, the chief executive officer now directly owns 137,553 shares in the company, valued at approximately $165,063.60. This represents a 7.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, December 18th, Krishna Vaddi bought 100,000 shares of Prelude Therapeutics stock. The stock was bought at an average price of $0.93 per share, for a total transaction of $93,000.00.

Prelude Therapeutics Stock Up 11.2 %

Shares of PRLD opened at $1.39 on Friday. The company has a market cap of $76.50 million, a price-to-earnings ratio of -0.78 and a beta of 1.49. Prelude Therapeutics Incorporated has a twelve month low of $0.80 and a twelve month high of $6.80. The company has a 50 day moving average of $1.11 and a two-hundred day moving average of $2.99.

Prelude Therapeutics (NASDAQ:PRLD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05. The firm had revenue of $3.00 million during the quarter. On average, sell-side analysts expect that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Prelude Therapeutics in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA raised its holdings in shares of Prelude Therapeutics by 5.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 549,530 shares of the company’s stock worth $1,138,000 after buying an additional 27,155 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Prelude Therapeutics by 8.2% in the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock worth $811,000 after buying an additional 29,765 shares during the last quarter. State Street Corp raised its holdings in shares of Prelude Therapeutics by 35.1% in the third quarter. State Street Corp now owns 286,046 shares of the company’s stock worth $592,000 after buying an additional 74,300 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Prelude Therapeutics by 885.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after buying an additional 157,218 shares during the last quarter. Finally, Walleye Capital LLC raised its holdings in shares of Prelude Therapeutics by 446.2% in the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after buying an additional 67,946 shares during the last quarter. Hedge funds and other institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.